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Background: In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of
tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with
a superior risk-benefit profile. In this retrospective study, we sought to establish the role of toremifene as an
endocrine therapy for premenopausal patients with estrogen and/or progesterone receptor positive breast cancer
besides tamoxifen.
Methods: Patients with early invasive breast cancer were selected from the breast tumor registries at the Sun
Yat-Sen Memorial Hospital (China). Premenopausal patients with endocrine responsive breast cancer who
underwent standard therapy and adjuvant therapy with toremifene or tamoxifen were considered eligible. Patients
with breast sarcoma, carcinosarcoma, concurrent contralateral primary breast cancer, or with distant metastases at
diagnosis, or those who had not undergone surgery and endocrine therapy were ineligible. Overall survival and
recurrence-free survival were the primary outcomes measured. Toxicity data was also collected and compared
between the two groups.
Results: Of the 810 patients reviewed, 452 patients were analyzed in the study: 240 received tamoxifen and 212
received toremifene. The median and mean follow up times were 50.8 and 57.3 months, respectively. Toremifene
and tamoxifen yielded similar overall survival values, with 5-year overall survival rates of 100% and 98.4%,
respectively (p= 0.087). However, recurrence-free survival was significantly better in the toremifene group than in
the tamoxifen group (p= 0.022). Multivariate analysis showed that recurrence-free survival improved independently
with toremifene (HR = 0.385, 95% CI = 0.154-0.961; p= 0.041). Toxicity was similar in the two treatment groups with
no women experiencing severe complications, other than hot flashes, which was more frequent in the toremifene
patients (p= 0.049). No patients developed endometrial cancer.
Conclusion: Toremifene may be a valid and safe alternative to tamoxifen in premenopausal women with
endocrine-responsive breast cancer.
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The optimal adjuvant therapy for premenopausal women
with hormone-responsive breast cancer still remains un-
clear despite the many clinical trials over the past 60 years
that have attempted to address this issue. Historically,
tamoxifen has been overlooked for the treatment of
breast cancer in premenopausal women, due to the false
belief that it is ineffective in this patient group. Indeed, it
was not until 1995 that the Early Breast Cancer Trialists'
Collaborative Group review unequivocally rejected this
misconception by demonstrating its efficacy in lowering
the rate of recurrence and mortality in premenopausal
women with HR-positive breast cancer [1]. In recent
years, the impact of endocrine therapies – primarily con-
sisting of tamoxifen and ovarian suppression strategies –
as an adjuvant treatment for premenopausal patients
with early breast cancer is well established. Moreover, the
expert panel of the 2009 St Gallen Conference accepted
tamoxifen (or tamoxifen plus ovarian suppression) as the
gold standard in endocrine therapy for this group [2].
Although there is mounting evidence to show that
tamoxifen has the potential to serve as adjuvant endo-
crine therapy for women of all ages with breast cancer,
questions on the long-term safety of tamoxifen have
been raised, due to the adverse event associated with this
therapy, including the increased risk of secondary endo-
metrial cancers, the formation of pulmonary embolism,
deep vein thrombosis and stroke [3-7]. More rarely, hep-
atotoxicity, ocular problems and an increased risk of
colorectal cancer have also been reported [8-16].
Recently, several alternative hormonal adjuvant ther-
apies for the treatment of breast cancer have become
available. Of these, toremifene is a synthetic analogue of
tamoxifen and, like tamoxifen, acts on the estrogen re-
ceptor. Although, the clinical efficacy of toremifene and
tamoxifen are comparable, both as palliative and post-
menopausal adjuvant therapies [17-23], toremifene and
tamoxifen are metabolized differently, due to a single
side chain chloride ion, leading to a more favorable tox-
icity profile [24-27]. Data on secondary endometrial can-
cer showed that the incidence of this cancer was lower
with toremifene than tamoxifen, prompting speculation
that toremifene may unmask existing endometrial
tumors rather than induce new events. Further, the risk
of stroke, pulmonary embolism, and cataract may be
lower with toremifene than with tamoxifen. Other evi-
dence suggests that the beneficial estrogen agonist
effects of toremifene, including changes in bone mineral
density and lipid profiles, were equivalent to those of
tamoxifen [28].
A prospective study using MRI demonstrated that
uterine changes associated with adjuvant drugs for
breast cancer occur exclusively in postmenopausal
patients receiving selective estrogen receptor modulators[29]; however, those studies mostly focused on postme-
nopausal patients. For premenopausal women receiving
tamoxifen, menopausal symptoms seemed to be a sig-
nificant concern, although the side effects of tamoxifen
alone were milder, with the exception of vaginal dis-
charge [30]. Thus, the gynecological side-effects of endo-
crine therapy differ according to menstrual status. This
may be related to the action of tamoxifen on the human
endometrium in postmenopausal women, where it has
simple estrogenic effects including hyperplasia, whereas
in premenopausal women it is linked with endometrial
cystic atrophy. Moreover, postmenopausal patients trea-
ted with tamoxifen may develop endometriosis, adeno-
myosis and leiomyomata. Tamoxifen also disrupts the
menstrual cycle and increases the incidence of ovarian
cysts in premenopausal breast cancer patients while in
postmenopausal patients it induces ovarian cystic
tumors and endometriomas [31,32]. In addition, tamoxi-
fen causes a decrease in bone mineral density in preme-
nopausal women [33,34]. However, in postmenopausal
women, only a mild bone-sparing effect during breast
cancer therapy has been reported, suggesting that in
these women, anti-estrogens may act as estrogen ago-
nists in the bone [35,36]. Taken together, such findings
prompt the question: as an adjuvant endocrine therapy
for premenopausal breast cancer patients, is toremifene
superior to tamoxifen?
The use of toremifene as an adjuvant endocrine ther-
apy for premenopausal patients with breast cancer is
rarely reported. Although one can point to a study on
632 patients aged under 50 receiving toremifene as an
adjuvant therapy, this report was aimed at tamoxifen
therapy in very young breast cancer patients, and it did
not compare the different effects of toremifene and tam-
oxifen, and did not evaluate the duration of treatment
[37]. In view of these limitations, the purpose of this
study was to compare these SERMs in premenopausal
estrogen or progesterone receptor positive women and
planned to perform a safety analysis, using a retrospect-
ive and cohort clinical study.
Methods
Patients
Patients with early invasive breast cancer who were trea-
ted between January 1998 and June 2009, were selected
by searching breast tumor registries at the Sun Yat-Sen
Memorial Hospital. Premenopausal patients with endo-
crine responsive breast cancer who underwent standard
therapy and adjuvant TAM/TOR for 5 years were eli-
gible for inclusion in our study. Their premenopausal
status was confirmed by measuring E2 and FSH levels
before surgery (in accordance with the menopausal cri-
terion of the 2010 National Comprehensive Cancer Net-
work). Patients were excluded if they had breast
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primary breast cancer, had distant metastasis at diagno-
sis, or had not undergone surgery in combination with
endocrine therapy.Procedures
In our study, all patients had unifocal, stage I–III inva-
sive breast cancer and had received local control in the
form of modified radical mastectomy (plus radiotherapy
if more than 3 lymph nodes were involved) and breast-
conserving surgery followed by radiotherapy. Chemo-
therapy and antiestrogen therapy were administered in
accordance with 2005 St Gallen treatment guidelines
(Table 1 and Table 2). Patients at an intermediate or
high risk of recurrence received six to eight cycles of
chemotherapy at 21-day intervals using one of the fol-
lowing regimens: cyclophosphamide 500 mg/m2, metho-
trexate 50 mg/m2, 5-fluorouracil 500 mg/m2 (CMF),
epirubicin 90 mg/m2, docetaxel 75 mg/m2 or paclitaxel
175 mg/m2 (ET); 5-fluorouracil 500 mg/m2, epirubicin
90 mg/m2, cyclophosphamide 500 mg/m2 (FEC); doce-
taxel 75 mg/m2 or paclitaxel 175 mg/m2, cyclophospha-
mide 500 mg/m2 (TC). In our department, antiestrogen
therapy was offered following chemotherapy for all
patients with endocrine responsive tumors regardless of
their risk category, whereby endocrine responsiveness
was defined as the presence of a ER and/or PR positive
status regardless expression level [38]. Past research hasTable 1 Definition of risk categories for breast cancer
patients who had undergone surgery, according to the
2005 St. Gallen guidelines
Risk Category Patient Features
Low risk Node negative AND all of the following features:
pT ≤2 cm,
Grade 1,
Absence of peritumoral vascular invasion,
HER2/neu gene neither overexpressed nor amplified,
Age ≥35 years




Presence of peritumoral vascular invasion,
HER2/neu gene overexpressed or amplified,
Age <35 years
Node positive (1–3 involved nodes) AND
HER2/neu gene neither overexpressed nor amplified
High risk Node positive (1–3 involved nodes) AND
HER2/neu gene overexpressed or amplified
Node positive (4 or more involved nodes)shown that daily toremifene (60 mg) is as effective as
daily tamoxifen (20 mg) in the treatment of postmeno-
pausal hormone-dependent breast cancer, hence in our
study, 20 mg of tamoxifen and 60 mg of toremifene were
given daily, orally, for 5 years [39]. Besides those listed
above, no other concomitant therapy was used, except
for medication for conditions unrelated to the breast
cancer. One doctor prescribed patients tamoxifen rou-
tinely, and another doctor toremifene.
The primary outcome measured was overall survival,
defined as the time from surgery to death from any
cause. The secondary endpoint was recurrence-free sur-
vival, which was defined as the time from surgery to first
evidence of recurrent disease (consisting of local re-
currence and distant metastasis) or death from breast
cancer. Patients known to be alive without recurrent dis-
ease or lost to follow-up at the time of analysis were
screened at the time of their last follow-up.
The study was also designed to collect data on the tox-
icity of the endocrine therapy. In this context, the
patients were interviewed over the telephone or asked to
fill out a questionnaire. At each visit, data was collected
on the following: nausea, presence of hot flashes, sweat-
ing, vaginal bleeding, vaginal dryness, leukorrhea, diar-
rhea, changes in mood or depression, the presence of
skin rashes or itching, and whether the patient had
experienced any symptoms or history of arterial or ven-
ous thromboses. The results of other tests including ultra-
sound/CT and blood test results were also collected by
searching the patients’ medical records. Follow-up was
performed until Feb 2011 and included: breast–abdomen
ultrasound, chest X-ray every 3 months within the first
2 years after surgery, breast–abdomen–transvaginal ultra-
sound, and chest X-ray every 6 months within 3–5 years.
Yearly mammograms, breast MR (if necessary), bone
scans, chest-abdomen CT and brain MR were also per-
formed, as was the evaluation of a number of biochemical
and histological markers.
Ethics
The study was conducted in accordance with the current
revision of the Declaration of Helsinki of the World
Medical Assembly, and in conformity with regulations
concerning clinical trials issued by medical authority at
the Sun Yat-Sen Memorial Hospital (No. 2,2010). The
study protocol and all relevant amendments were
reviewed and approved by Ethics Committees of the Sun
Yat-Sen Memorial Hospital.
Statistical methods
Statistical analyses were performed using SPSS 13.0 for
Windows (SPSS Inc., Chicago IL,USA). Correlation was
assessed using a χ² test and survival rates were estimated
using a Kaplan–Meier test. A log-rank test was used to
Table 2 Differences between treatment modalities as per the 2005 St. Gallen guidelines
Risk Category Endocrine responsive Endocrine response uncertain Endocrine nonresponsive
Low risk ET or Nil ET or Nil Not applicable
Intermediate risk ET alone, or CT! ET CT
CT! ET (CT + ET)
(CT + ET)
High risk CT! ET CT! ET CT
(CT + ET) (CT + ET)
Abbreviations: ET, endocrine therapy; Nil, no adjuvant systemic therapy; CT, chemotherapy.
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used to balance the risk factors for prognosis between
groups. The prognostic factors included in the multivari-
ate analysis model were: patient age, tumor size, lymph
node status, histological grade, Her-2 status, chemother-
apy, type of adjuvant endocrine therapy drug, and local
control. A p value of less than 0.05 was considered to be
significant.Results
Patients in our study all presented with self-detected
breast cancer. Figure 1 shows the number of patients
assessed at every stage in the study. A total of 810
patients with breast cancer were reviewed, of whom 452
were eligible for inclusion in the study. The median fol-
low up time was 50.8 months, the mean follow up time
was 57.3 months (range: 17.3 - 209 months, SD
29.5 months). The clinical and pathological characteris-
tics of eligible patients are shown in Table 3. The median
age of the group was 43 years (IQR 38.0 - 46.8), andFigure 1 Schematic illustrating the overall study design. Survival outco
tamoxifen or toremifene treated premenopausal breast cancer patients wemean age was 41.8 ± 5.9 years. No significant difference
in the distribution of these variables was noted, except
for the type of local control. Similarly, no significant dif-
ference was observed between the two treatment groups
of patients who died of breast cancer (p= 0.138).
Cox regression analysis for all patients included in the
study showed that recurrence-free survival in the tore-
mifene group was significantly longer than in the
tamoxifen group (HR = 0.385, 95% CI = 0.154-0.961;
p = 0.041; Table 4). However, multivariate analysis
confirmed that no factor was independently related to
overall survival (Table 5). We did further Kaplan–Meier
analysis of survival with patients in the two treatment
groups (Figure 2, Table 6). For overall survival (OS), the
3-year, 5-year and 8-year OS was better in the toremi-
fene patients, who were all alive at the time of last fol-
low up. However, stratified log-rank tests for unadjusted
analyses, did not reveal a significant difference. For
recurrence-free survival, survival outcomes were
improved following toremifene treatment compared
with tamoxifen (p= 0.022).mes, recurrence-free outcomes and the presence of side effects in
re evaluated.
Table 3 Patient characteristics characterized according to
whether the patients received tamoxifen (TAM) or
toremifene (TOR) treatment



























III 47 52 0.530
Unknown 1 3
Risk of recurrence 0.313
Low 11 15
Intermediate or 229 197
high 0.024
Local control 117 130
BCS + RT 90 57
Modified 33 25







Differences between the two groups were evaluated using a χ2 test.
Table 4 Multivariate analysis of recurrence-free survival
between patients treated with tamoxifen (TAM) and
toremifene (TOR)






Local control 0.933(0.521-1.672) 0.816
Chemotherapy 1.249(0.898-1.739) 0.187
TAM-TOR 0.385(0.154-0.961) 0.041
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enced breast cancer recurrence during the mean follow-
up period of 50.2 months. Of these patients, 23 (9.6%) of
those taking tamoxifen and 6 (2.8%) of those taking tore-
mifene had a local, regional, distant, or multi-site recur-
rence (Table 7). In the tamoxifen group, there were 12
patients who had multi-site recurrence, of which 7 had
more than one site of distant metastases, 5 who had
concurrent locoregional and one or more sites of distant
recurrence. In the toremifene group, there was 1 patient
who had concomitant bone and liver metastases. We
noted a higher number of local recurrences as well as
distant recurrences in women taking tamoxifen; how-
ever, the differences between the two groups were not
statistically significant. Five (1.1%) of the women died
during the study period, all of whom had been offered
tamoxifen (2.1%; Table 7). Of those 5 women, all of the
deaths were attributed to breast cancer.
Our study shows a trend toward similar rates of
subjective and objective events in the women treated
with tamoxifen or toremifene (Table 8). No women
experienced severe adverse events such as thrombo-
embolic or cerebrovascular complications. Hot flashes
were the only side effect, which when compared be-
tween the two groups was statistically significant.Table 5 Multivariate analysis of overall survival between







Local control 0.630(0.150-2.643) 0.528
Chemotherapy 0.993(0.441-2.234) 0.987
TAM-TOR 0.000(0.000-6E + 174) 0.955
15.0010.005.000.00

























Figure 2 A. Kaplan–Meier analysis was used to evaluate overall survival in tamoxifen (TAM) or toremifene (TOR) treated
premenopausal breast cancer patients (p=0.087). B. Kaplan–Meier analysis was used to evaluate recurrence-free survival in tamoxifen (TAM)
or toremifene (TOR) treated premenopausal breast cancer patients (p= 0.022).
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patients in toremifene group who underwent meno-
pause during endocrine therapy (p = 0.716), and some
of them turned to aromatase inhibitors (AIs; Table 9,p = 0.242). Table 9 also lists the common reasons for
discontinuing the drug regimen besides death or re-
currence, and shows that patient compliance was
similar in the two groups.
Table 8 Side effects and adverse events in
premenopausal breast cancer patients treated with
tamoxifen or toremifene
Tamoxifen Toremifene p value
Subjective
Sweating 59 63 0.220
Hot flash 56 67 0.049
Vaginal discharge 12 7 0.369
Leucorrhea increasing 22 31 0.072
Vaginal dryness 18 13 0.566
Vaginal bleeding 3 4 0.869
Skin pruritus 19 18 0.824
Depression 17 22 0.213
Skinrash 15 13 0.959
Nausea or vomit 3 8 0.082
Diarrhea 3 3 1.000
Asomnia 22 25 0.361
Weightgain 50 45 0.918
Fracture 2 1 1.000
Ostalgia 49 49 0.488
Hyper-menorrhea 2 7 0.124
Blurred vision 5 3 0.857
Objectives
Ovarian cysts 12 18 0.137
Teratoma 1 1 1.000
Uterine fibroids 25 35 0.057
Hysterectomy 9 17 0.052
Table 6 Comparison of recurrence and death rates in
premenopausal patients with breast cancer treated with
tamoxifen (TAM) and toremifene (TOR)
TAM (n= 240) TOR (n = 212) P value
Overall survival(%) 97.9 100 0.087
3 years 99.5 100
5 years 98.4 100
8 years 95.5 100
Recurrence-free survival(%) 90.4 97.2 0.022
3 years 94.8 98.8
5 years 90.7 95.6
8 years 88.9 89.3
Differences between the groups were evaluated using log-rank tests for
unadjusted analyses.
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Results of this retrospective analysis suggest that tore-
mifene and tamoxifen have similar efficacies in premeno-
pausal breast cancer patients, and have comparable side
effects. Although the standard therapy for premenopausal
women with breast cancer is tamoxifen, some patients are
offered treatment with ovarian suppression in conjunction
with AI therapy, either because tamoxifen is contraindi-
cated or they have an intolerance to tamoxifen, or because
their physicians believe that the AIs are superior based on
data from postmenopausal women. Although AIs are in-
creasingly being used in breast cancer patients, the im-
portance of classic drugs for premenopausal patientsUterine polyps 2 3 0.889
Cervical cyst 2 0 0.501
Endometrial hyperplasia 15 22 0.110
Osteoporosis 4 2 0.796
Fatty liver 25 20 0.728
Hemangiomas 4 3 1.000
Hepatic cyst 8 5 0.536
Cholecystic polips 3 4 0.869
Transaminase step-up 2 7 0.426
Splenic hemangioma 0 1 0.469
Cataracts 0 1 0.469
Table 7 Site of recurrence and the cause of death in
premenopausal breast cancer patients treated with
tamoxifen or toremifene
Tamoxifen (n = 240) Toremifene (n = 212)














Breast cancer 4 0
Other reasons 1 0
In the tamoxifen group, there were 12 patients with multiple site of
recurrence, of which 7 had more than one site where distant metastases were
detected, 5 had concurrent locoregional and one or more sites of distant
recurrence. In the toremifene group, there was 1 patient who had
concomitant bone and liver metastases.should not be ignored. Chemotherapy in young breast
cancer patients frequently causes abrupt menopause, al-
though many menstruate again following chemotherapy,
especially very young patients. Further, some postmeno-
pausal patients recommence menstruation after treatment
with AIs. As is widely known, AIs are harmful for preme-
nopausal patients. However, with respect to toremifene
clinical trials have shown that toremifene does not in-
crease the incidence of adverse events for moderate to se-
vere mastalgia patients [40]. Other reports have shown
that toremifene (60 mg daily) has no substantial negative
Table 9 Adherence to therapy in premenopausal breast






Total 45 31 0.242






Cervical cyst 1 0
Uterine fibroids 1 0
Ostalgia 1 0
Skinrash 2 0
Endometrial hyperplasia 5 0




To fear adverse effect 1 4
Economic reason 1 0








Vaginal bleeding 0 1
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women and may actually have a minor favorable influence
[41]. In this situation, when considering safety tamoxifen
or toremifene should be considered. However, few studies
have investigated the therapeutic role of toremifene as ad-
juvant endocrine therapy for premenopausal breast cancer
patients. Since there are more young breast cancer
patients in Asian countries, than in other regions,
researchers from Asia are increasingly becoming inter-
ested in this issue. In a Korean study, toremifene was sug-
gested to young patients, but this study failed to compare
the impact and side effect of tamoxifen and toremifene,
and the treatment duration was not followed up [37]. An-
other study, from the Seoul National University College of
Medicine, evaluated the use of toremifene as an adjuvant
hormonal therapy for estrogen receptor positive early
breast cancer patients in terms of its therapeutic efficacy
and effect on the endometrium, as compared with tamoxi-
fen, but the study did not consider how treatment affected
these patients’ menstrual cycles. In our study, therapy dur-
ation was investigated, in addition to the effect of treat-
ment on the menstrual cycle, by evaluating estradiol and
follicle stimulating hormone levels.
Multivariate analysis showed that toremifene was asso-
ciated with improved recurrence-free survival and thatno factor was independently related to overall survival.
Future studies may need to increase samples sizes in
order to establish the optimal therapy. Moreover, our
study was also limited by a lack of investigation as the
expression of the estrogen and progesterone receptor
and changes in HER-2 status.
All objective adverse events were obtained by search-
ing the internal hospital database and medical records
during the period when the patients were undergoing
endocrine therapy. With respect to the gynecological
side-effect such as ovarian cysts and uterine fibroids,
these always occurred a few months after taking the
drugs, and were mostly so mild and stable that we did
not need to disrupt the endocrine therapy. As for other
side effects, such as skin rash and nausea, the patients
were frequently unable to recall when these events had
occurred, the seriousness, or the possible causes.
In our study, most patients were treated concurrently,
and following an almost identical protocol of surgical
intervention plus chemotherapy, but with differing adju-
vant endocrine therapies. There was no difference in
age, tumor size, tumor grade, degree of lymph node in-
volvement, or risk of recurrence between the two
cohorts. Wherever possible we attempted breast-
conserving surgery unless there were positive margin, in
which case radical mastectomy was performed. As the
women who received breast-conserving surgery always
had a significantly lower tumor load, other factors
should also considered, such as the tumor-breast ratio
and tumor location. Similarly, as BCS is the marriage of
breast conserving surgery and radiation therapy, the side
effects of radiotherapy should not be ignored. In China,
breast-conserving surgery costs are more expensive than
modified radical mastectomy because of the surgery
costs, concomitant radiotherapy, and the additional
pathology required. These factors were explained to each
of the patients, and the type of surgery was then based
on input from both patients’ and doctors’. In spite of the
issues around cost and side effects and in light of the
traditional bias towards breast-conserving surgery, some
patients elected for radical mastectomy.
Inclusion of only one center in our study may be
related to the clustering of surgeries between the
two cohorts, which may explain why there was a
nearly 13% difference in local treatment modality be-
tween the two groups and possibly reflects the fact
that doctors influenced patients during the talk be-
fore surgery. Among young women, those who
received BCS are more likely to experience local re-
currence, while long-term survival was similar for
those who received BCS compared to those who
underwent modified radical mastectomy [42]. In our
study, BCS was higher in the toremifene group but
the risk of recurrence was significantly lower. The
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with few lost to follow-up, and a long follow-up
period (median >50 months).
Compliance with treatment was suboptimal in both
arms of the study, with 23 women on tamoxifen 20
women on toremifene ceasing therapy after a few
months (p= 0.961; Figure 1). Many turned to traditional
Chinese medicine and refused any further consultation.
These patients were not included in the final analysis.
However, patients who discontinued tamoxifen and tore-
mifene within 5 years because of menopause or other
unavoidable reasons were still included, in accordance
with intent-to-treat analysis.
Conclusions
This work represents the first study comparing the clin-
ical efficacy and side effects of tamoxifen and toremifene
in premenopausal breast cancer patients. The results
demonstrated that toremifene has similar effect as tam-
oxifen, but can prevent further recurrence. These find-
ings are important for clinicians treating premenopausal
breast cancer patients who are beginning adjuvant endo-
crine therapy.
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